thalidomide has been researched along with Besnier-Boeck Disease in 36 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide use in cutaneous sarcoidosis is based on data from small case series or case reports." | 9.19 | A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. ( Chevrant-Breton, J; Chosidow, O; Cosnes, A; D'Incan, M; Desseaux, K; Droitcourt, C; Dupin, N; Dupuy, A; Joly, P; Juillard, C; Lacour, JP; Lebrun-Vignes, B; Misery, L; Porcher, R; Revuz, J; Rybojad, M; Sassolas, B; Tazi, A; Valeyre, D, 2014) |
| "Limited data report thalidomide improves cutaneous sarcoidosis; no benefit has been reported for pulmonary localization." | 9.16 | Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. ( Antonelli, A; Barachini, P; Calabrese, R; Carpi, A; Cei, G; Cristofani, R; Fazzi, P; Manni, E; Piazza, S; Siciliano, G, 2012) |
| "Thalidomide efficacy and tolerance in patients with cutaneous sarcoidosis merits further evaluation in a controlled trial." | 9.11 | Treatment of cutaneous sarcoidosis with thalidomide. ( Cordoliani, F; Dupuy, A; Lebbé, C; Morel, P; Nguyen, YT; Rybojad, M; Vignon-Pennamen, MD, 2004) |
| "Thalidomide was an effective form of treatment for chronic cutaneous sarcoidosis." | 9.10 | Thalidomide for chronic sarcoidosis. ( Baughman, RP; Judson, MA; Lower, EE; Moller, DR; Teirstein, AS, 2002) |
| "Data from ten patients with sarcoidosis treated with thalidomide between January 1998 and March 1999 were collected from delivery authorizations and analyzed." | 7.71 | [Sarcoidosis: thalidomide treatment in ten patients]. ( Bressieux, JM; Cosnes, A; Estines, O; Revuz, J; Roujeau, JC; Wolkenstein, P, 2001) |
| "A patient with sarcoidosis was treated with thalidomide for disfiguring and painful steroid unresponsive sarcoidal granulomas of the skin." | 7.70 | Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. ( Koblenzer, PS; Lee, JB, 1998) |
| " Because administration of low doses of thalidomide has been successful in treating other inflammatory diseases, it was used in a patient with systemic sarcoidosis who was unresponsive to corticosteroids and in a patient with pulmonary sarcoidosis, in whom Kaposi's sarcoma developed after a course of corticosteroid therapy." | 7.69 | Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. ( Bonaccorsi, P; Calvieri, S; Carlesimo, M; Giustini, S; Rossi, A, 1995) |
| "Thalidomide has a different toxicity profile than corticosteroids or immunosuppressives." | 6.42 | Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents. ( Baughman, RP; Lower, EE, 2004) |
| "Thalidomide was given to 2 patients with EOS (a 16-year-old girl and an 8-year-old boy) at an initial dosage of 2 mg/kg/day, and the dosage was increased if necessary." | 5.36 | Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: its possible action and mechanism. ( Manki, A; Morishima, T; Takemoto, K; Tsuge, M; Yamamoto, M; Yashiro, M; Yasui, K, 2010) |
| "Thalidomide is an immunomodulatory agent that acts to inhibit production of tumor-necrosis factor-alpha (TNF-alpha), an important mediator in CNS inflammation, by enhancing TNF-alpha mRNA degradation." | 5.34 | Thalidomide for acute treatment of neurosarcoidosis. ( Hammond, ER; Kaplin, AI; Kerr, DA, 2007) |
| "Thalidomide was effective for muscular, cutaneous, and pulmonary involvement in our patient." | 5.32 | Successful treatment of muscle sarcoidosis with thalidomide. ( Lochmüller, H; Meindl, T; Müller-Felber, W; Schlotter-Weigel, B; Walter, MC, 2003) |
| "Thalidomide use in cutaneous sarcoidosis is based on data from small case series or case reports." | 5.19 | A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. ( Chevrant-Breton, J; Chosidow, O; Cosnes, A; D'Incan, M; Desseaux, K; Droitcourt, C; Dupin, N; Dupuy, A; Joly, P; Juillard, C; Lacour, JP; Lebrun-Vignes, B; Misery, L; Porcher, R; Revuz, J; Rybojad, M; Sassolas, B; Tazi, A; Valeyre, D, 2014) |
| "Limited data report thalidomide improves cutaneous sarcoidosis; no benefit has been reported for pulmonary localization." | 5.16 | Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. ( Antonelli, A; Barachini, P; Calabrese, R; Carpi, A; Cei, G; Cristofani, R; Fazzi, P; Manni, E; Piazza, S; Siciliano, G, 2012) |
| "Thalidomide efficacy and tolerance in patients with cutaneous sarcoidosis merits further evaluation in a controlled trial." | 5.11 | Treatment of cutaneous sarcoidosis with thalidomide. ( Cordoliani, F; Dupuy, A; Lebbé, C; Morel, P; Nguyen, YT; Rybojad, M; Vignon-Pennamen, MD, 2004) |
| "Thalidomide was an effective form of treatment for chronic cutaneous sarcoidosis." | 5.10 | Thalidomide for chronic sarcoidosis. ( Baughman, RP; Judson, MA; Lower, EE; Moller, DR; Teirstein, AS, 2002) |
| "The widely accepted standard therapy for cutaneous sarcoidosis includes corticosteroids, antimalarials, and methotrexate." | 4.84 | Cutaneous sarcoidosis therapy updated. ( Badgwell, C; Rosen, T, 2007) |
| "Data from ten patients with sarcoidosis treated with thalidomide between January 1998 and March 1999 were collected from delivery authorizations and analyzed." | 3.71 | [Sarcoidosis: thalidomide treatment in ten patients]. ( Bressieux, JM; Cosnes, A; Estines, O; Revuz, J; Roujeau, JC; Wolkenstein, P, 2001) |
| "A patient with sarcoidosis was treated with thalidomide for disfiguring and painful steroid unresponsive sarcoidal granulomas of the skin." | 3.70 | Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. ( Koblenzer, PS; Lee, JB, 1998) |
| " Because administration of low doses of thalidomide has been successful in treating other inflammatory diseases, it was used in a patient with systemic sarcoidosis who was unresponsive to corticosteroids and in a patient with pulmonary sarcoidosis, in whom Kaposi's sarcoma developed after a course of corticosteroid therapy." | 3.69 | Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. ( Bonaccorsi, P; Calvieri, S; Carlesimo, M; Giustini, S; Rossi, A, 1995) |
| "Sarcoidosis is a systemic granulomatous disease that affects numerous organs, commonly manifesting at the lungs and skin." | 2.52 | TNF-α: a treatment target or cause of sarcoidosis? ( Amber, KT; Bloom, R; Hertl, M; Mrowietz, U, 2015) |
| "Thalidomide was initially approved by the U." | 2.46 | Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. ( Ladizinski, B; Levis, WR; Sanchez, MR; Shannon, EJ, 2010) |
| "Thalidomide was developed in the 1950s as a sedative drug and withdrawn in 1961 because of its teratogenic effects, but has been rediscovered as an immuno-modulatory drug." | 2.46 | [Thalidomide as immunomodulatory drug: pharmacological actions and its indications]. ( Yasui, K, 2010) |
| "Thalidomide was first introduced in the 1950s as a sedative but was quickly removed from the market after it was linked to cases of severe birth defects." | 2.43 | Thalidomide: dermatological indications, mechanisms of action and side-effects. ( Hsu, S; Huang, DB; Pang, KR; Tyring, SK; Wu, JJ, 2005) |
| "Thalidomide has a different toxicity profile than corticosteroids or immunosuppressives." | 2.42 | Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents. ( Baughman, RP; Lower, EE, 2004) |
| "Thalidomide was given to 2 patients with EOS (a 16-year-old girl and an 8-year-old boy) at an initial dosage of 2 mg/kg/day, and the dosage was increased if necessary." | 1.36 | Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: its possible action and mechanism. ( Manki, A; Morishima, T; Takemoto, K; Tsuge, M; Yamamoto, M; Yashiro, M; Yasui, K, 2010) |
| "Thalidomide is an immunomodulatory agent that acts to inhibit production of tumor-necrosis factor-alpha (TNF-alpha), an important mediator in CNS inflammation, by enhancing TNF-alpha mRNA degradation." | 1.34 | Thalidomide for acute treatment of neurosarcoidosis. ( Hammond, ER; Kaplin, AI; Kerr, DA, 2007) |
| "Thalidomide was effective for muscular, cutaneous, and pulmonary involvement in our patient." | 1.32 | Successful treatment of muscle sarcoidosis with thalidomide. ( Lochmüller, H; Meindl, T; Müller-Felber, W; Schlotter-Weigel, B; Walter, MC, 2003) |
| "Our data suggest that thalidomide treatment of sarcoidosis results in granuloma differentiation to a Th1-type cellular immune response usually associated with protective immunity to tuberculosis and tuberculoid leprosy." | 1.31 | Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. ( Kaplan, G; Kikuchi, T; Krueger, JG; Oliver, SJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (8.33) | 18.7374 |
| 1990's | 5 (13.89) | 18.2507 |
| 2000's | 16 (44.44) | 29.6817 |
| 2010's | 11 (30.56) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, W | 2 |
| Zhong, LQ | 1 |
| Li, WD | 1 |
| Wu, SJ | 1 |
| Song, HM | 1 |
| Droitcourt, C | 1 |
| Rybojad, M | 2 |
| Porcher, R | 1 |
| Juillard, C | 1 |
| Cosnes, A | 2 |
| Joly, P | 1 |
| Lacour, JP | 1 |
| D'Incan, M | 1 |
| Dupin, N | 1 |
| Sassolas, B | 1 |
| Misery, L | 1 |
| Chevrant-Breton, J | 1 |
| Lebrun-Vignes, B | 1 |
| Desseaux, K | 1 |
| Valeyre, D | 1 |
| Revuz, J | 2 |
| Tazi, A | 1 |
| Chosidow, O | 1 |
| Dupuy, A | 2 |
| Huddleston, SM | 1 |
| Houser, KH | 1 |
| Walton, RC | 1 |
| Amber, KT | 1 |
| Bloom, R | 1 |
| Mrowietz, U | 1 |
| Hertl, M | 1 |
| Xiong, X | 1 |
| Ling, Y | 1 |
| Yang, K | 1 |
| Sun, W | 1 |
| Su, Z | 1 |
| Lu, Y | 1 |
| Antoniu, SA | 1 |
| Yasui, K | 2 |
| Yashiro, M | 1 |
| Tsuge, M | 1 |
| Manki, A | 1 |
| Takemoto, K | 1 |
| Yamamoto, M | 1 |
| Morishima, T | 1 |
| Ladizinski, B | 1 |
| Shannon, EJ | 1 |
| Sanchez, MR | 1 |
| Levis, WR | 1 |
| Ahn, SW | 1 |
| Kim, KT | 1 |
| Youn, YC | 1 |
| Kwon, OS | 1 |
| Kim, YB | 1 |
| Baughman, RP | 4 |
| Judson, MA | 2 |
| Ingledue, R | 1 |
| Craft, NL | 1 |
| Lower, EE | 3 |
| Fazzi, P | 1 |
| Manni, E | 1 |
| Cristofani, R | 1 |
| Cei, G | 1 |
| Piazza, S | 1 |
| Calabrese, R | 1 |
| Antonelli, A | 1 |
| Siciliano, G | 1 |
| Barachini, P | 1 |
| Carpi, A | 1 |
| Teirstein, AS | 1 |
| Moller, DR | 2 |
| Lynch, JP | 1 |
| Walter, MC | 1 |
| Lochmüller, H | 1 |
| Schlotter-Weigel, B | 1 |
| Meindl, T | 1 |
| Müller-Felber, W | 1 |
| Vizel', AA | 1 |
| Guryleva, ME | 1 |
| Vizel', EA | 1 |
| Nasretdinova, GP | 1 |
| Nguyen, YT | 1 |
| Cordoliani, F | 1 |
| Vignon-Pennamen, MD | 1 |
| Lebbé, C | 1 |
| Morel, P | 1 |
| Wu, JJ | 1 |
| Huang, DB | 1 |
| Pang, KR | 1 |
| Hsu, S | 1 |
| Tyring, SK | 1 |
| Badgwell, C | 1 |
| Rosen, T | 1 |
| Hammond, ER | 1 |
| Kaplin, AI | 1 |
| Kerr, DA | 1 |
| Barriere, H | 1 |
| Prigent, F | 1 |
| Ouazzani, W | 1 |
| Carlesimo, M | 1 |
| Giustini, S | 1 |
| Rossi, A | 1 |
| Bonaccorsi, P | 1 |
| Calvieri, S | 1 |
| Rousseau, L | 1 |
| Beylot-Barry, M | 1 |
| Doutre, MS | 1 |
| Beylot, C | 1 |
| Grasland, A | 1 |
| Pouchot, J | 1 |
| Chaumaizière, D | 1 |
| Aitken, G | 1 |
| Vinceneux, P | 1 |
| Lee, JB | 1 |
| Koblenzer, PS | 1 |
| Saano, V | 1 |
| Moraes, M | 1 |
| Russo, G | 1 |
| Estines, O | 1 |
| Wolkenstein, P | 1 |
| Bressieux, JM | 1 |
| Roujeau, JC | 1 |
| Hoch, O | 1 |
| Müller, S | 1 |
| Büttner, G | 1 |
| Mensing, H | 2 |
| Oliver, SJ | 1 |
| Kikuchi, T | 1 |
| Krueger, JG | 1 |
| Kaplan, G | 1 |
| Ochsendorf, F | 1 |
| Kaufmann, R | 1 |
| Picard, C | 1 |
| Crickx, B | 1 |
| Perron, J | 1 |
| Lecerf, V | 1 |
| Belaïch, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Controlled Trial of Thalidomide vs Placebo in Skin Sarcoidosis[NCT00305552] | Phase 3 | 40 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis[NCT00794274] | Phase 2/Phase 3 | 15 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel[NCT02298491] | Phase 4 | 4 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total number of lesions assessed at 1 year (NCT02298491)
Timeframe: 1 year
| Intervention | lesions (Number) |
|---|---|
| H.P. Acthar Gel | 5 |
13 reviews available for thalidomide and Besnier-Boeck Disease
| Article | Year |
|---|---|
TNF-α: a treatment target or cause of sarcoidosis?
Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Etanercept; Granuloma; Hum | 2015 |
Targeting the TNF-alpha pathway in sarcoidosis.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Eta | 2010 |
Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.
Topics: Behcet Syndrome; Dermatitis; Erythema Nodosum; Humans; Immunomodulation; Lupus Erythematosus, Cutane | 2010 |
[Thalidomide as immunomodulatory drug: pharmacological actions and its indications].
Topics: Behcet Syndrome; Child; Female; Humans; Immunologic Factors; Male; NF-kappa B; Sarcoidosis; Thalidom | 2010 |
Treatment of sarcoidosis -- from a basic science point of view.
Topics: Etanercept; Granuloma; Humans; Immunoglobulin G; Immunosuppressive Agents; Interleukins; Pentoxifyll | 2003 |
Difficult treatment issues in sarcoidosis.
Topics: Antibodies, Monoclonal; Antimalarials; Azathioprine; Cyclophosphamide; Decision Making; Humans; Immu | 2003 |
[The role of tumor necrosis factor in pathogenesis and treatment of sarcoidosis].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Humans; Immunosuppressive Agents; Infliximab; Sarcoido | 2003 |
Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents.
Topics: Chronic Disease; Clinical Trials as Topic; Facial Dermatoses; Humans; Immunosuppressive Agents; Sarc | 2004 |
Thalidomide: dermatological indications, mechanisms of action and side-effects.
Topics: Adult; Behcet Syndrome; Dermatologic Agents; Erythema; Graft vs Host Disease; Histiocytosis, Langerh | 2005 |
Cutaneous sarcoidosis therapy updated.
Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Allopurinol; Animals; Anti-Inflammatory Agents | 2007 |
[New therapeutic application of thalidomide].
Topics: Autoimmune Diseases; Colitis, Ulcerative; Erythema Multiforme; Female; Histiocytosis; Humans; Immuno | 1996 |
Thalidomide and its dermatologic uses.
Topics: Acquired Immunodeficiency Syndrome; Behcet Syndrome; Dermatologic Agents; Erythema Nodosum; Facial D | 2001 |
[Florid cutaneous sarcoidosis. Therapeutic difficulties].
Topics: Adrenal Cortex Hormones; Cyclosporins; Facial Dermatoses; Humans; Male; Middle Aged; PUVA Therapy; S | 1989 |
5 trials available for thalidomide and Besnier-Boeck Disease
| Article | Year |
|---|---|
A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis.
Topics: Adult; Aged; Double-Blind Method; Female; France; Humans; Immunosuppressive Agents; Male; Middle Age | 2014 |
Efficacy and safety of apremilast in chronic cutaneous sarcoidosis.
Topics: Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Sarcoidosis; Severity of Illness Index; Skin D | 2012 |
Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids.
Topics: Adult; Aged; Contraindications; Dose-Response Relationship, Drug; Drug Resistance; Feasibility Studi | 2012 |
Thalidomide for chronic sarcoidosis.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; | 2002 |
Treatment of cutaneous sarcoidosis with thalidomide.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; Male; Middle Aged | 2004 |
18 other studies available for thalidomide and Besnier-Boeck Disease
| Article | Year |
|---|---|
Thalidomide may be an effective drug for Blau syndrome: a case report.
Topics: Arthritis; Female; Humans; Nod2 Signaling Adaptor Protein; Sarcoidosis; Synovitis; Thalidomide; Uvei | 2022 |
Thalidomide for recalcitrant nodular scleritis in sarcoidosis.
Topics: Female; Humans; Immunosuppressive Agents; Middle Aged; Recurrence; Sarcoidosis; Scleritis; Thalidomi | 2014 |
Case of sarcoidosis presenting with symmetrical facial keratotic papules.
Topics: Cheek; Female; Hepatic Duct, Common; Humans; Keratosis; Lymph Nodes; Lymphadenopathy; Middle Aged; S | 2018 |
Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: its possible action and mechanism.
Topics: Adolescent; Arthrography; Cells, Cultured; Child; Cytokines; Female; Humans; Immunosuppressive Agent | 2010 |
Isolated spinal cord neurosarcoidosis diagnosed by cord biopsy and thalidomide trial.
Topics: Adrenal Cortex Hormones; Biopsy; Central Nervous System Diseases; Female; Humans; Immunosuppressive | 2011 |
Successful treatment of muscle sarcoidosis with thalidomide.
Topics: Adult; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Muscular Diseases; Sarcoi | 2003 |
Thalidomide for acute treatment of neurosarcoidosis.
Topics: Adult; Brain; Granuloma; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Proprio | 2007 |
[Cutaneous sarcoidosis. Treatment with thalidomide].
Topics: Humans; Sarcoidosis; Skin Diseases; Thalidomide | 1983 |
[Cutaneous sarcoidosis. Treatment with thalidomide].
Topics: Humans; Leg Ulcer; Sarcoidosis; Thalidomide | 1983 |
Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.
Topics: Aged; Female; Humans; Middle Aged; Sarcoidosis; Sarcoidosis, Pulmonary; Sarcoma, Kaposi; Skin Diseas | 1995 |
Cutaneous sarcoidosis successfully treated with low doses of thalidomide.
Topics: Adult; Cicatrix; Female; Fibrosis; Humans; Immunosuppressive Agents; Sarcoidosis; Skin Diseases; Tha | 1998 |
[Effectiveness of thalidomide treatment during cutaneous sarcoidosis].
Topics: Dermatologic Agents; Female; Humans; Middle Aged; Sarcoidosis; Skin Diseases; Thalidomide; Treatment | 1998 |
Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report.
Topics: Dermatologic Agents; Drug Administration Schedule; Facial Dermatoses; Female; Fingers; Glucocorticoi | 1998 |
[Sarcoidosis: thalidomide treatment in ten patients].
Topics: Chronic Disease; Dermatologic Agents; Drug Administration Schedule; Humans; Immunosuppressive Agents | 2001 |
[Thalidomide in the treatment of cutaneous and systemic sarcoidosis].
Topics: Adult; Dermatologic Agents; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Male; Middle | 2001 |
Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement.
Topics: Adult; Antigens, CD; Dendritic Cells; Dermatologic Agents; Female; Flow Cytometry; HLA-DR Antigens; | 2002 |
[New indication for thalidomide?].
Topics: Humans; Immunosuppressive Agents; Sarcoidosis; Thalidomide | 2002 |
[Comment on O. Hoch et al.: "Thalidomide in treatment of cutaneous and systemic sarcoidosis"].
Topics: Humans; Sarcoidosis; Skin Diseases; Thalidomide; Treatment Outcome | 2002 |